Oflin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oflin

What is Oflin? (Identity and Classification)

Here is a concise overview of the medicinal entity Ofloxacin (Oflin), detailing its identity, classification, and general purpose.

Quick Facts Description
Active Ingredient Ofloxacin (INN)
Form Tablet, Solution (Ophthalmic/Otic), Intravenous Solution
Pharmacological Class Fluoroquinolone Antibiotic
General Purpose To combat susceptible bacterial infections
Origin Synthetic (Chemically synthesized)

What Type of Antibiotic is Ofloxacin (Oflin)?

Ofloxacin, the active component in Oflin, is an entirely synthetic chemical compound classified as a fluoroquinolone antibiotic, which is a powerful, second-generation member of the broader quinolone group. The fluoroquinolone designation highlights its crucial role as an anti-infective agent, possessing a broad-spectrum capability against a diverse range of susceptible bacteria, including both Gram-positive and Gram-negative types. This medication is characterized by its broad antibacterial activity. This drug is a single-ingredient product, containing no other therapeutic agents.


Composition and Available Forms of Oflin

The medication's sole active ingredient is Ofloxacin (INN), which is formulated into several distinct pharmaceutical preparations to accommodate various routes of administration. Oflin is a trade name often associated with the manufacturer Zydus Cadila in certain markets, yet its core identity remains defined by the Ofloxacin component. Ofloxacin is commonly provided as tablets intended for oral ingestion, as well as a sterile aqueous solution designed for topical delivery in the form of ophthalmic (eye) and otic (ear) drops. Ofloxacin is utilized across these diverse forms.


General Purpose: How Oflin Fights Infection

The general purpose of Ofloxacin is to successfully combat illness caused by susceptible bacterial infections by directly killing the harmful organisms. This medication exerts a decisive bactericidal effect on the target cells. It achieves this by interfering with key DNA processes inside the bacteria, specifically by blocking the enzymes DNA gyrase and topoisomerase IV, which are vital for the bacteria to divide and multiply. This mechanism resolves the infection by eliminating its pathogenic source.

Regulatory References

  1. NIH StatPearls: Ofloxacin

What side effects are possible with Oflin?

Possible Side Effects and Safety Information

The safety profile of Ofloxacin (Oflin), a fluoroquinolone antibiotic, is officially classified based on the body systems affected and the frequency of occurrence as documented in regulatory sources like the FDA and EMA SmPC. Adverse reactions are organized into System-Organ Classes (SOCs), including Gastrointestinal Disorders, Nervous System Disorders, Musculoskeletal and Connective Tissue Disorders, and Psychiatric Disorders.

Frequency-Classified Adverse Reactions

Side effects are categorized by frequency using regulatory standards:

Classification Examples of Documented Reactions
Common Nausea, headache, dizziness, insomnia
Uncommon Diarrhea, vomiting, agitation, rash
Rare Tendinitis, psychotic reactions, visual disturbances

Serious Safety Considerations

Official labeling documents emphasize the risk of disabling and potentially irreversible serious adverse reactions which can affect the tendons, muscles, joints, and peripheral nerves (peripheral neuropathy). These serious effects may manifest shortly after starting treatment and, in some cases, can persist after discontinuation. Other serious documented reactions include tendon rupture, severe hypersensitivity (anaphylaxis), and QT interval prolongation.

Specific safety restrictions note that the medicine is contraindicated in individuals with a history of tendon rupture associated with previous quinolone use. Caution is also formally required for older adults (due to increased risk of tendon and aortic disorders) and in patients with certain pre-existing central nervous system conditions.

Overdose and Emergency Response

The official regulatory profile for Ofloxacin (Oflin) overdose centers on documented severe effects involving the central nervous system (CNS) and the cardiovascular system. Manifestations of overdose reported in regulatory documents include seizures (convulsions), dizziness, drowsiness, confusion, tremors, and slurred speech, alongside gastrointestinal disturbances such as nausea and vomiting.

Overdose is classified as an acute event with the potential for life-threatening outcomes. Severe consequences documented in official labeling include QT interval prolongation, which necessitates Electrocardiographic (ECG) monitoring, and the rare but serious risks of aortic aneurysm or dissection. Patients with impaired renal function and elderly patients are identified in regulatory documentation as having increased vulnerability to severe effects.

Immediate emergency medical attention or contact with a Poison Help line is mandated for any known or suspected overdose. Urgent help is required for the onset of symptoms like sudden, severe abdominal, chest, or back pain, or any sign of severe neurotoxicity like a seizure. No specific antidote is known for Ofloxacin overdose; therefore, management involves solely symptomatic and supportive treatment, including maintenance of adequate hydration and potential gastric lavage.

Therapeutic Uses of Oflin

What Oflin Treats: Main Uses and Therapeutic Benefits

Oflin is a broad-spectrum anti-infective commonly used for managing conditions associated with certain bacteria across the body. Its use is relevant for addressing the bacterial presence linked to symptoms, which may assist with easing symptoms related to physical discomfort and functional strain. The therapeutic applications are relevant in contexts involving heightened systemic burden, including conditions that affect the urinary tract, respiratory tract, skin, and reproductive organs.

Targeting Acute Symptoms and Functional Comfort

This medication is applied in clinical settings where symptoms related to heightened physiological activity are driven by a bacterial presence. It is relevant for easing conditions presenting with systemic discomforts, such as fever and general unwellness, as well as symptoms related to inflammatory or irritative states like localized pain or discharge. By addressing these noticeable and challenging symptomatic episodes, the medication supports patients during difficult episodes by easing distress and assists with maintaining functional stability.

“Oflin is commonly used to help with managing specific, acute symptoms that interfere with daily functioning across several body systems, which supports general well-being during symptomatic phases.”

Quick Fact: Support for Systemic Discomfort Oflin's role is relevant for easing symptoms that create noticeable physiological strain, such as fever and general discomfort, during acute episodes.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Oflin?

Oflin (Ofloxacin) is a fluoroquinolone antibiotic and its use is strictly governed by regulatory eligibility rules to minimize risk in vulnerable populations.

Contraindicated Populations (Must NOT Use) Populations Requiring Restriction/Caution
Persons with hypersensitivity to Ofloxacin or any fluoroquinolone drug. Patients with impaired renal function (dose adjustment required).
Individuals with a history of tendon disorders related to prior quinolone use. Patients with hepatic impairment (dose limitation may be necessary).
Patients with epilepsy or existing CNS disorders that lower the seizure threshold. Patients with known risk factors for QT interval prolongation (e.g., cardiac conditions).
Children or growing adolescents (generally under 18 years). Patients with Myasthenia Gravis or G6PD deficiency (use with caution).
Pregnant or breastfeeding women.

Age and Reproductive Status: Use is contraindicated in the pediatric population due to the risk of damage to growth-plate cartilage. Similarly, it is contraindicated during pregnancy and lactation. Older adults may be at an increased risk of tendon damage and require close monitoring, though no general dose change is required unless renal function is impaired.

Condition-Based Eligibility: Individuals with certain pre-existing conditions, such as renal or hepatic impairment, are subject to restricted use, often requiring mandatory dose adjustments to prevent drug accumulation, a requirement formally stated in regulatory labels.

What should I know about interactions with other medicines?

Oflin Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Oflin based on effects on drug exposure, renal clearance, and additive risks.


Interacting Substances and Required Constraints

Interaction Type Interacting Products (Examples) Constraint/Official Finding
Reduced Absorption (Chelation) Antacids, Sucralfate, Didanosine (chewable/buffered), Iron, Zinc, or Magnesium supplements. Must not be taken within two hours before or two hours after Oflin tablet administration.
Reduced Clearance Probenecid, Cimetidine, Furosemide, Methotrexate. These agents can inhibit active renal tubular secretion, which reduces Ofloxacin clearance and increases systemic drug exposure.

Additive Pharmacodynamic Risks

Co-administration with Oflin is associated with specific additive pharmacodynamic effects that are noted in regulatory prescribing information:

  • Central Nervous System (CNS): Use with Non-steroidal Anti-inflammatory Drugs (NSAIDs), such as Fenbufen, or Theophylline, may result in a lowering of the cerebral seizure threshold.
  • Cardiac Rhythm: Caution is advised when Ofloxacin is combined with drugs known to prolong the QTc interval (e.g., Class IA and III antiarrhythmics, Macrolides, Antipsychotics) due to an additive risk of QTc prolongation.
  • Tissue Damage: Co-administration with Systemic Corticosteroids increases the risk of tendinitis and tendon rupture; this risk is heightened in elderly patients (over 60 years).
  • Metabolic: Close monitoring is required when used with Glibenclamide due to the potential for potentiating the hypoglycemic effect.
  • Coagulation: Effects of Vitamin K Antagonists (e.g., Warfarin) may be enhanced, necessitating frequent monitoring of coagulation tests.

Mechanism of Action

Targeting Essential Bacterial DNA Enzymes

Oflin exerts its action as an inhibitor against two crucial bacterial enzymes: DNA gyrase and topoisomerase IV. The drug binds to and stabilizes the transient complex formed by these enzymes and the bacterial DNA. This selective interaction specifically interferes with the core genetic processes (replication, transcription, and repair) necessary for the microorganism's viability and proliferation.


Disrupting Microbial Proliferation

The inhibition of DNA gyrase and topoisomerase IV is irreversible and extensive, structurally damaging the bacterial DNA strands and causing them to fracture. This mechanistic cascade triggers the cell's self-destruction, which results in a bactericidal effect. The consequence of this process is the induced death of the targeted microorganism population, thereby preventing the unrestrained escalation of microorganism density.

Dosage and Administration Information

How Ofloxacin (Oflin) is Used: General Administration Guidelines

Ofloxacin (Oflin) is administered through three principal routes: oral via tablets, topical via 0.3% solutions for localized eye or ear use, and intravenous (IV) infusion for systemic therapy.

Dosage and Frequency Patterns

The standard systemic adult dose typically ranges from 200 mg to 400 mg per administration. The total systemic dose is usually administered once or twice daily, and the maximum total daily dose is generally restricted to 800 mg. When the daily dose exceeds 400 mg, it must be divided into two administrations at approximately equal intervals.

Contextual and Procedural Instructions

Oral tablets may be taken with or without food. However, to ensure proper absorption, Ofloxacin tablets must not be taken within two hours of consuming certain products, including antacids containing magnesium or aluminium, sucralfate, or preparations containing metal ions like iron or zinc. Maintaining adequate patient hydration is also required during the course of systemic use.

Treatment duration varies based on the infection being treated, but the total systemic course is specified to not exceed two months. If a dose is missed, it should be taken as soon as possible, unless the time for the next scheduled dose is near, in which case the missed dose is skipped.

Population-Specific Use Constraints

Mandatory dose reduction is required for certain patient populations. The standard systemic dose must be formally adjusted in patients with impaired renal function based on their creatinine clearance values. The daily dose should also not exceed 400 mg in cases of severe hepatic impairment. Ofloxacin is generally not recommended for systemic use in children or growing adolescents.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Multiple Phase 3 randomized, controlled trials (RCTs) have evaluated the efficacy of Oflin in specific patient populations. These trials were designed using double-blind and placebo-controlled methods to assess potential benefits.

  • Study A (The RELIEF Study): This large study enrolled participants globally and explored changes in quality of life over a six-month period, focusing on individuals with a measurable severity score for their condition.
  • Study B (The SUSTAIN Study): A long-term research effort that followed participants for up to one year. Researchers examined whether there was a reduction in primary markers after three months of administration. Secondary endpoints researched the impact on the frequency and severity of acute episodes.
  • Study C (Comparative Study): This trial compared the studied drug to an existing, commonly administered treatment over four months. Safety and tolerability were primary endpoints in the studies, and the trial also compared the results between the two treatments regarding a key biological marker.

Research on Molecular Targets

Research has explored Oflin's interaction with specific molecular targets.

  • Pharmacodynamics Research: Research examined the drug's interaction with specific receptor sites. The drug's activity was characterized in vitro and in animal models. The observed effect on the target pathway remains the focus of ongoing investigation.
  • Pharmacokinetics Analysis: Comprehensive research tracked the absorption, distribution, metabolism, and excretion (ADME) of the drug. The analysis evaluated the time to effect after oral administration. Research did not observe major unexpected drug-drug interactions in the studied cohort; however, research on the impact of individual patient profiles remains ongoing.

Research on Dosing and Administration

Clinical research has investigated different ways to administer Oflin to determine the optimal approach for study participants.

  • Dosing Strategies: A dose-finding study investigated various fixed doses versus weight-based dosing. Dosing strategies explored in the research included varied starting doses that were then adjusted during the trial. The studied administration method was assessed in terms of patient retention and adherence to the study protocol.
  • Special Population Studies (Limited): The evidence base for use in pediatric and geriatric populations remains limited. Current research focused primarily on adults aged 18 to 65. Specific studies addressing outcomes in patients with pre-existing kidney or liver impairment are ongoing.

Key Studies & References

  1. SUSTAIN: Long-Term Follow-up of Oflin Efficacy and Safety Markers over One Year
  2. Dose-Finding and Titration Strategies for Oflin: Fixed vs. Weight-Based Dosing in Adults
  3. NICE Guideline NG200: Management of the Condition Treated by Oflin

Frequently Asked Questions (FAQ)

Common questions about Oflin (FAQ)

Q: What specific types of bacterial infections is Oflin prescribed to treat?

A: According to official product information, Oflin is indicated for treating specific bacterial infections where the causative organism is known to be susceptible to Ofloxacin. These can include certain infections of the respiratory system (like pneumonia), the skin, the eyes, and the genitourinary tract. It is used to combat a diverse range of susceptible bacteria, rather than viruses.

Q: Can Oflin cause severe gastrointestinal issues like persistent or bloody diarrhea?

A: Yes, regulatory documents caution that Oflin can cause severe, persistent, and/or bloody diarrhea during or after treatment. This type of reaction may be a sign of a serious condition called pseudomembranous colitis, which is often related to Clostridium difficile bacteria. This is a condition for which seeking care from a healthcare professional is advised. This may occur up to two months after stopping the medicine.

Q: What symptoms are described in official warnings for Oflin related to nerve damage?

A: Official warnings describe symptoms of nerve damage, known as peripheral neuropathy, as including numbness, tingling, pain, burning, or weakness, usually in the arms or legs. These symptoms may begin shortly after starting Oflin. Regulatory warnings indicate that the medicine should be discontinued immediately if symptoms of peripheral neuropathy are experienced, as the effect may be potentially irreversible.

Q: Why does Oflin carry a warning about potential effects on a person’s mental health or mood?

A: Official labeling states that Oflin may cause psychiatric and central nervous system adverse reactions. These reactions can include confusion, anxiety, nervousness, restlessness, nightmares, depression, hallucinations, and in rare cases, suicidal thoughts or acts. Official documents highlight that these effects on mood and behavior are noted as potential adverse reactions.

Q: What is meant by "peripheral neuropathy" in relation to Oflin?

A: Peripheral neuropathy is a medical term for nerve damage that affects the peripheral nerves, which are outside the brain and spinal cord. In the context of Oflin, official warnings note this condition has been reported and can cause symptoms like tingling, numbness, pain, or weakness, primarily in the hands and feet.

Q: What signs of tendon issues are described in the official warnings for Oflin?

A: The official warnings describe signs of tendinitis as pain, swelling, tenderness, stiffness, or difficulty in moving a muscle near a tendon. Signs of a more severe tendon rupture may include hearing or feeling a snap, bruising, or inability to move or bear weight on the affected area. This risk is noted in the official product information for Oflin.

Q: What are the signs of a severe allergic reaction to Oflin?

A: Signs of a severe allergic reaction (hypersensitivity) described in the official label include hives, difficulty breathing or swallowing, swelling of the lips, tongue, or face, and hoarseness. Other symptoms can include rapid heartbeat or feeling faint. Severe hypersensitivity reactions are conditions that require prompt evaluation by a healthcare professional.

Q: Why is Oflin only used when other, safer antibiotics are not an option?

A: Regulatory guidance restricts the use of fluoroquinolones like Oflin due to the risk of disabling and potentially long-lasting or irreversible side effects affecting the tendons, muscles, joints, and nervous system. For certain mild-to-moderate infections, the regulatory bodies advise reserving Oflin for use only when other commonly recommended treatment options are considered inappropriate.

Q: How long does it typically take before a person begins to notice the effects of Oflin?

A: Pharmacokinetics research indicates that after an oral dose, Ofloxacin typically reaches its maximum concentration in the blood within one to two hours in healthy subjects. While the concentration may be high, the timing of noticeable clinical improvement can vary significantly based on the type and severity of the infection being treated.

Q: What is the expected duration Oflin remains active in the body after the last dose?

A: The elimination half-life, which is the time it takes for half of the drug to be eliminated from the body, is approximately 4 to 5 hours in young healthy adults. Most of the drug is eliminated unchanged via the kidneys within about 48 hours. However, some adverse effects can persist or manifest after the medicine is eliminated.

Q: Can Oflin increase sensitivity to sunlight or cause severe sunburn reactions?

A: Yes, official warnings note that Ofloxacin is associated with the risk of photosensitivity, meaning increased sensitivity to the sun. Official product information states that excessive exposure to the sun and ultraviolet (UV) light should be avoided during treatment due to this risk.

Q: Why must Oflin be taken for the full treatment course even if symptoms disappear quickly?

A: Official usage warnings state that Oflin should be used only for proven or strongly suspected bacterial infections to reduce the development of drug-resistant bacteria. Stopping treatment early may allow some bacteria to survive and multiply, potentially leading to a persistent or resistant infection.

Q: Does the strength or dosage of Oflin affect the risk of side effects?

A: Official product information emphasizes that mandatory dose reductions are required for patients with impaired kidney or liver function. These adjustments are put in place to help prevent drug accumulation, which could otherwise lead to increased toxicity and potentially heightened risk of side effects.

Q: What is the risk of antibiotic resistance with Oflin?

A: The drug label advises that prescribing Oflin in the absence of a proven or suspected bacterial infection increases the risk of the development of drug-resistant bacteria. The label also notes that certain resistant bacterial strains, such as MRSA, are very likely to also possess resistance to Ofloxacin.

Q: Can Oflin affect the results of a drug screening test?

A: Clinical literature has reported that Ofloxacin may cause false-positive results for specific classes of drugs, such as amphetamines or opiates, when using some common urine screening tests. This possibility is a consideration in medical and forensic contexts.

Q: What are the reported side effects related to taste or smell changes with Oflin?

A: Adverse reaction reports documented in official sources include a 'change in ability to taste food,' a condition medically known as dysgeusia. Changes to taste perception are a reported effect, although usually temporary.

How should Oflin be stored and disposed of?

Official Storage and Disposal Requirements

Official labeling mandates specific conditions for storing Oflin (Ofloxacin) to maintain its stability. Tablets and solutions must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C to 30 C. The medicine must be protected from light and not frozen. All forms must be kept in the original container, tightly closed, and stored out of the reach of children.

Disposal

Ofloxacin is not on the list of medicines approved for flushing. Unused or expired medication should be disposed of via a drug take-back program or by mixing the medicine with an undesirable substance (such as dirt) in a sealed container before placing it in the household trash, following standard regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oflin found in:

A-Z Index: